vs
OMNICELL, INC.（OMCL）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
OMNICELL, INC.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.5倍（$309.9M vs $207.3M），OMNICELL, INC.净利率更高（3.7% vs -62.0%，领先65.7%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 14.9%），OMNICELL, INC.自由现金流更多（$38.6M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 5.8%）
Omnicell是总部位于美国加州山景城的跨国医疗科技企业，专注于为医院及各类医疗机构提供药品管理自动化系统，同时面向零售药房推出用药依从性包装与患者互动软件，旗下产品使用Omnicell及EnlivenHealth两大品牌。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
OMCL vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $309.9M | $207.3M |
| 净利润 | $11.4M | $-128.6M |
| 毛利率 | 45.3% | — |
| 营业利润率 | 60.1% | -54.7% |
| 净利率 | 3.7% | -62.0% |
| 营收同比 | 14.9% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $0.25 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | $309.9M | — | ||
| Q4 25 | $314.0M | $207.3M | ||
| Q3 25 | $310.6M | $159.9M | ||
| Q2 25 | $290.6M | $166.5M | ||
| Q1 25 | $269.7M | $139.3M | ||
| Q4 24 | $306.9M | $164.6M | ||
| Q3 24 | $282.4M | $139.5M | ||
| Q2 24 | $276.8M | $147.0M |
| Q1 26 | $11.4M | — | ||
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $5.5M | $-180.4M | ||
| Q2 25 | $5.6M | $-115.0M | ||
| Q1 25 | $-7.0M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $8.6M | $-133.5M | ||
| Q2 24 | $3.7M | $-131.6M |
| Q1 26 | 45.3% | — | ||
| Q4 25 | 41.5% | — | ||
| Q3 25 | 43.3% | — | ||
| Q2 25 | 43.9% | — | ||
| Q1 25 | 41.1% | — | ||
| Q4 24 | 46.2% | — | ||
| Q3 24 | 43.3% | — | ||
| Q2 24 | 41.3% | — |
| Q1 26 | 60.1% | — | ||
| Q4 25 | 0.1% | -54.7% | ||
| Q3 25 | 2.7% | -106.9% | ||
| Q2 25 | 2.8% | -64.8% | ||
| Q1 25 | -4.3% | -102.6% | ||
| Q4 24 | 4.0% | -74.3% | ||
| Q3 24 | 2.3% | -94.6% | ||
| Q2 24 | 1.2% | -79.1% |
| Q1 26 | 3.7% | — | ||
| Q4 25 | — | -62.0% | ||
| Q3 25 | 1.8% | -112.8% | ||
| Q2 25 | 1.9% | -69.0% | ||
| Q1 25 | -2.6% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | 3.1% | -95.7% | ||
| Q2 24 | 1.3% | -89.5% |
| Q1 26 | $0.25 | — | ||
| Q4 25 | $-0.05 | $-1.28 | ||
| Q3 25 | $0.12 | $-1.81 | ||
| Q2 25 | $0.12 | $-1.17 | ||
| Q1 25 | $-0.15 | $-1.57 | ||
| Q4 24 | $0.34 | $-1.34 | ||
| Q3 24 | $0.19 | $-1.40 | ||
| Q2 24 | $0.08 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $239.2M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.3B | $-80.0M |
| 总资产 | $2.0B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | $239.2M | — | ||
| Q4 25 | $196.5M | $421.0M | ||
| Q3 25 | $180.1M | $202.5M | ||
| Q2 25 | $399.0M | $176.3M | ||
| Q1 25 | $386.8M | $127.1M | ||
| Q4 24 | $369.2M | $174.0M | ||
| Q3 24 | $570.6M | $150.6M | ||
| Q2 24 | $556.8M | $480.7M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.2B | $-80.0M | ||
| Q3 25 | $1.2B | $9.2M | ||
| Q2 25 | $1.3B | $151.3M | ||
| Q1 25 | $1.3B | $144.2M | ||
| Q4 24 | $1.2B | $255.0M | ||
| Q3 24 | $1.2B | $346.8M | ||
| Q2 24 | $1.2B | $432.4M |
| Q1 26 | $2.0B | — | ||
| Q4 25 | $2.0B | $1.5B | ||
| Q3 25 | $1.9B | $1.2B | ||
| Q2 25 | $2.1B | $1.3B | ||
| Q1 25 | $2.2B | $1.3B | ||
| Q4 24 | $2.1B | $1.5B | ||
| Q3 24 | $2.3B | $1.5B | ||
| Q2 24 | $2.3B | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $54.5M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $38.6M | $-100.8M |
| 自由现金流率自由现金流/营收 | 12.5% | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 4.80× | — |
| 过去12个月自由现金流最近4个季度 | $110.8M | $-472.0M |
8季度趋势，按日历期对齐
| Q1 26 | $54.5M | — | ||
| Q4 25 | $30.4M | $-99.8M | ||
| Q3 25 | $28.3M | $-91.4M | ||
| Q2 25 | $42.8M | $-108.3M | ||
| Q1 25 | $25.9M | $-166.5M | ||
| Q4 24 | $56.3M | $-79.3M | ||
| Q3 24 | $22.8M | $-67.0M | ||
| Q2 24 | $58.7M | $-77.0M |
| Q1 26 | $38.6M | — | ||
| Q4 25 | $22.6M | $-100.8M | ||
| Q3 25 | $18.5M | $-92.7M | ||
| Q2 25 | $31.0M | $-110.7M | ||
| Q1 25 | $14.8M | $-167.8M | ||
| Q4 24 | $47.2M | $-79.5M | ||
| Q3 24 | $13.9M | $-68.6M | ||
| Q2 24 | $49.1M | $-79.0M |
| Q1 26 | 12.5% | — | ||
| Q4 25 | 7.2% | -48.6% | ||
| Q3 25 | 6.0% | -58.0% | ||
| Q2 25 | 10.7% | -66.5% | ||
| Q1 25 | 5.5% | -120.5% | ||
| Q4 24 | 15.4% | -48.3% | ||
| Q3 24 | 4.9% | -49.2% | ||
| Q2 24 | 17.8% | -53.7% |
| Q1 26 | — | — | ||
| Q4 25 | 2.5% | 0.5% | ||
| Q3 25 | 3.1% | 0.8% | ||
| Q2 25 | 4.1% | 1.5% | ||
| Q1 25 | 4.1% | 1.0% | ||
| Q4 24 | 3.0% | 0.1% | ||
| Q3 24 | 3.1% | 1.2% | ||
| Q2 24 | 3.5% | 1.4% |
| Q1 26 | 4.80× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 5.18× | — | ||
| Q2 25 | 7.58× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.64× | — | ||
| Q2 24 | 15.72× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OMCL
| Product revenues | $174.8M | 56% |
| Service revenues | $135.1M | 44% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
